Skip to content
Screener

ClearPoint Neuro CLPT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Abbott logo
AbbottABT
$109.22B+30.0%
Boston Scientific logo
Boston ScientificBSX
$44.35B+10.5%
IAR
Integra LifeSciencesIART
$3.56B-2.8%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$22.8B-0.3%
Medtronic logo
MedtronicMDT
$93.03B+1.5%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$873.02M+4.3%

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$433.47M+44.7%
Enterprise value$460.54M+57.0%
P/S10.7×+1.8×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221890
Line itemMarch 31, 2026 / (Unaudited)December 31, 2025
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2026 and December 31, 2025; 29,986,639 and 29,368,760 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively300294
Additional paid-in capital239,468238,995
Shares to be issued5,5355,641
Accumulated deficit(226,462)(216,910)
Total stockholders’ equity18,84128,020
Total liabilities and stockholders’ equity$93,416$97,747

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is ClearPoint Neuro's total liabilities & equity?
ClearPoint Neuro (CLPT) reported total liabilities & equity of $93.42M in Q1 2026.
How has ClearPoint Neuro's total liabilities & equity changed year-over-year?
ClearPoint Neuro's total liabilities & equity increased by 210.7% year-over-year, from $30.07M to $93.42M.
What is the long-term trend for ClearPoint Neuro's total liabilities & equity?
Over 5 years (2020 to 2025), ClearPoint Neuro's total liabilities & equity has grown at a 27.1% compound annual growth rate (CAGR), from $29.52M to $97.75M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about ClearPoint Neuro's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude